project . 2021 - 2027 . On going

ATTACK

Analysis of the T cell’s Tactical Arsenal for Cancer Killing
Open Access mandate for Publications and Research DataOpen Access mandate for ... European Commission
  • Funder: European CommissionProject code: 951329 Call for proposal: ERC-2020-SyG
  • Funded under: H2020 | ERC | ERC-SyG Overall Budget: 9,999,020 EURFunder Contribution: 9,999,020 EUR
  • Status: On going
  • Start Date
    01 May 2021
    End Date
    30 Apr 2027
  • Detailed project information (CORDIS)
Description
The ATTACK consortium will develop a new biotechnology based on harnessing a previously unknown natural cytotoxic mechanism of T cells to fight cancer. Cytotoxic T cells (CTL) protect us against intracellular pathogens and cancer by killing infected and cancerous cells. It has been believed that CTL operate on two different time scales of killing by releasing soluble cytotoxic proteins from dense core granules into the immunological synapse between the T cell and target cells (seconds/minutes) and by FasL-mediated apoptosis (hours/days). Members of the ATTACK consortium have independent observations that converge on a previously unknown weapon in the T cell tact...
Description
The ATTACK consortium will develop a new biotechnology based on harnessing a previously unknown natural cytotoxic mechanism of T cells to fight cancer. Cytotoxic T cells (CTL) protect us against intracellular pathogens and cancer by killing infected and cancerous cells. It has been believed that CTL operate on two different time scales of killing by releasing soluble cytotoxic proteins from dense core granules into the immunological synapse between the T cell and target cells (seconds/minutes) and by FasL-mediated apoptosis (hours/days). Members of the ATTACK consortium have independent observations that converge on a previously unknown weapon in the T cell tact...
Any information missing or wrong?Report an Issue